CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05879419
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:54.046547+00:00
Published At: 2025-12-03T00:00:00+00:00
Record Updated At: 2025-12-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Rheumatoid Arthritis", "Spondylitis, Ankylosing", "Spondyloarthritis", "Systemic Lupus Erythematosus", "Sjogren\u0027s Syndrome", "Systemic Sclerosis", "Idiopathic Inflammatory Myopathies", "Vasculitis, Systemic", "Juvenile Idiopathic Arthritis", "Dermatomyositis, Juvenile", "Beh\u00e7et Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-03"
protocolSection.identificationModule.nctId: "NCT05879419"
protocolSection.identificationModule.officialTitle: "Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX\u00ae) in Patients With Autoimmune Rheumatic Diseases"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.